Lyndra’s Series E Cash Expected To Get Weekly Risperidone To An FDA Filing

Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.

Money in sack on wooden table
Lyndra raises $101m in private equity cash while awaiting Phase III data

Through years of private equity fund raises and partnerships, Lyndra Therapeutics has been building up its strategy to bring once-weekly or monthly oral medications to the health care system. With a $101m series E fundraising and a related commercial rights alliance with Sun Pharmaceutical Industries Ltd. unveiled on 21 December, the Watertown, MA-based company appears to be getting closer to that goal.

Key Takeaways
  • Drug delivery specialist Lyndra raises $101m in series E cash, with some of the money coming from Sun Pharma in exchange for commercial rights to its lead product candidate.

In January, Lyndra plans to release data from a Phase III pharmacokinetic study of LYN-005, its weekly, oral formulation of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.